Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020). Identified a novel coronavirus from patients with pneumonia and proposed a probable bat origin for SARS-CoV-2.
Pekar, J. E. et al. The molecular epidemiology of multiple zoonotic origins of SARS-CoV-2. Science 377, 960–966 (2022).
Holmes, E. C. The emergence and evolution of SARS-CoV-2. Annu. Rev. Virol. 11, 21–42 (2024).
Worobey, M. et al. The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic. Science 377, 951–959 (2022).
Liu, W. J. et al. Surveillance of SARS-CoV-2 at the Huanan Seafood Market. Nature 631, 402–408 (2024).
Bloom, J. D. Importance of quantifying the number of viral reads in metagenomic sequencing of environmental samples from the Huanan Seafood Market. Virus Evol. 10, vead089 (2024).
Crits-Christoph, A. et al. Genetic tracing of market wildlife and viruses at the epicenter of the COVID-19 pandemic. Cell 187(5468-5482), e5411 (2024).
World Health Organization. WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19 – 11 March 2020 https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020 (WHO, 2020). Marked the date the WHO officially declared the COVID-19 outbreak a global pandemic.
Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269 (2020).
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021). Confirmed the high efficacy and safety profile of the Moderna mRNA-1273 COVID-19 vaccine.
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020). Demonstrated the safety and efficacy of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine.
Steele, M. K. et al. Estimated number of COVID-19 infections, hospitalizations, and deaths prevented among vaccinated persons in the US, december 2020 to september 2021. JAMA Netw. Open 5, e2220385 (2022).
Baggen, J., Vanstreels, E., Jansen, S. & Daelemans, D. Cellular host factors for SARS-CoV-2 infection. Nat. Microbiol. 6, 1219–1232 (2021).
V’Kovski, P., Kratzel, A., Steiner, S., Stalder, H. & Thiel, V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol. 19, 155–170 (2021).
Steiner, S. et al. SARS-CoV-2 biology and host interactions. Nat. Rev. Microbiol. 22, 206–225 (2024).
DeGrace, M. M. et al. Defining the risk of SARS-CoV-2 variants on immune protection. Nature 605, 640–652 (2022). Defined how different SARS-CoV-2 variants affect immune protection, particularly vaccine effectiveness.
Mellis, I. A. et al. Do existing COVID-19 vaccines need to be updated in 2025? Preprint at bioRxiv https://doi.org/10.1101/2025.05.02.651777 (2025).
Guo, C. et al. Antigenic and virological characteristics of SARS-CoV-2 variants BA.3.2, XFG, and NB.1.8.1. Lancet Infect. Dis. 25, e374–e377 (2025).
Khare, S. et al. GISAID’s role in pandemic response. China CDC Wkly 3, 1049–1051 (2021).
Elbe, S. & Buckland-Merrett, G. Data, disease and diplomacy: GISAID’s innovative contribution to global health. Glob. Chall. 1, 33–46 (2017).
Rambaut, A. et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat. Microbiol. 5, 1403–1407 (2020).
Wang, Q. et al. KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2. Lancet Infect. Dis. 25, e133–e134 (2025).
Mallajosyula, V. et al. CD8+ T cells specific for conserved coronavirus epitopes correlate with milder disease in COVID-19 patients. Sci. Immunol. 6, eabg5669 (2021).
Augusto, D. G. et al. A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection. Nature 620, 128–136 (2023).
Anderson, D. E. et al. Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2. Emerg. Microbes Infect. 9, 900–902 (2020).
Korber, B. et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812–827.e819 (2020). Tracked the spike D614G mutation; showed it increased the infectivity of the COVID-19 virus.
Hou, Y. J. et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science 370, 1464–1468 (2020).
Plante, J. A. et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature 592, 116–121 (2021).
Weissman, D. et al. D614G spike mutation increases SARS CoV-2 susceptibility to neutralization. Cell Host Microbe 29, 23–31.e24 (2021).
Roemer, C. et al. SARS-CoV-2 evolution in the Omicron era. Nat. Microbiol. 8, 1952–1959 (2023).
Fischer, W. et al. HIV-1 and SARS-CoV-2: patterns in the evolution of two pandemic pathogens. Cell Host Microbe 29, 1093–1110 (2021).
Hill, V. et al. The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in the UK. Virus Evol. 8, veac080 (2022).
Shen, X. et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe 29, 529–539.e523 (2021).
Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130–135 (2021).
Gellenoncourt, S. et al. The spike-stabilizing D614G mutation interacts with S1/S2 cleavage site mutations to promote the infectious potential of SARS-CoV-2 variants. J. Virol. 96, e0130122 (2022).
Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221–224 (2020). Determined the structural basis for SARS-CoV-2 spike protein binding to the human ACE2 receptor.
Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292.e286 (2020).
Wang, P. et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe 29, 747–751.e744 (2021).
Faria, N. R. et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science 372, 815–821 (2021).
Dejnirattisai, W. et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell 184, 2939–2954.e2939 (2021).
Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell 184, 2348–2361.e2346 (2021).
Cox, M. et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat. Rev. Microbiol. 21, 112–124 (2023).
Lopez Bernal, J. et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N. Engl. J. Med. 385, 585–594 (2021).
Andrews, N. et al. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N. Engl. J. Med. 386, 1532–1546 (2022).
Abu-Raddad, L. J., Chemaitelly, H., Butt, A. A. & National Study Group for, C.-V. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 variants. N. Engl. J. Med. 385, 187–189 (2021).
Olawoye, I. B. et al. Emergence and spread of two SARS-CoV-2 variants of interest in Nigeria. Nat. Commun. 14, 811 (2023).
Halfmann, P. J. et al. Characterization of the SARS-CoV-2 B.1.621 (Mu) variant. Sci. Transl. Med. 14, eabm4908 (2022).
Cherian, S. et al. SARS-CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. Microorganisms 9, 1542 (2021).
Furusawa, Y. et al. In SARS-CoV-2 delta variants, Spike-P681R and D950N promote membrane fusion, Spike-P681R enhances spike cleavage, but neither substitution affects pathogenicity in hamsters. EBioMedicine 91, 104561 (2023).
Liu, Y. et al. Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. Cell Rep. 39, 110829 (2022).
Kuzmina, A. et al. Changes within the P681 residue of spike dictate cell fusion and syncytia formation of Delta and Omicron variants of SARS-CoV-2 with no effects on neutralization or infectivity. Heliyon 9, e16750 (2023).
Ridgway, H. et al. Molecular epidemiology of SARS-CoV-2: the dominant role of arginine in mutations and infectivity. Viruses 15, 309 (2023).
Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276–280 (2021).
Tada, T. et al. Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera. iScience 24, 103341 (2021).
Liu, J. et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature 596, 273–275 (2021).
Liu, C. et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184, 4220–4236.e4213 (2021).
Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 603, 679–686 (2022).
Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602, 664–670 (2022).
Cheng, S. M. S. et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat. Med. 28, 486–489 (2022).
Carreno, J. M. et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 602, 682–688 (2022).
Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657–663 (2022). Revealed that the Omicron variant escapes most SARS-CoV-2 neutralizing antibodies.
Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676–681 (2022).
Zhou, T. et al. Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. Science 376, eabn8897 (2022).
Iketani, S. et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 604, 553–556 (2022).
Zhang, X. et al. SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance. Signal Transduct. Target. Ther. 6, 430 (2021).
Qu, P. et al. Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant. Cell Host Microbe 30, 1518–1526.e1514 (2022).
US Food and Drug Administration. Update on COVID-19 Vaccine Booster Composition https://www.fda.gov/vaccines-blood-biologics/update-covid-19-vaccine-booster-composition (US FDA, 2023).
Planas, D. et al. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies. Nat. Commun. 14, 824 (2023).
Uraki, R. et al. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB. Lancet Infect. Dis. 23, 30–32 (2023).
Wang, Q. et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 186, 279–286.e278 (2023).
Uraki, R. et al. Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate. iScience 26, 108147 (2023).
Yamasoba, D. et al. Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant. Lancet Infect. Dis. 23, 655–656 (2023).
Uraki, R. et al. Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo. Cell Rep. 42, 113580 (2023).
Jian, F. et al. Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455-456 synergistically enhances antibody evasion and ACE2 binding. PLoS Pathog. 19, e1011868 (2023).
Zhang, Q. E. et al. SARS-CoV-2 Omicron XBB lineage spike structures, conformations, antigenicity, and receptor recognition. Mol. Cell 84, 2747–2764.e2747 (2024).
Uriu, K. et al. Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant. Lancet Infect. Dis. 23, e460–e461 (2023).
Wang, Q. et al. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. Nature 624, 639–644 (2023).
Yang, X. et al. Immune escape of BA.2.86 is comparable to XBB subvariants from the plasma of BA.5- and BA.5-XBB-convalescent subpopulations. J. Med. Virol. 96, e29417 (2024).
Qu, P. et al. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants. Cell 187, 585–595.e586 (2024).
Liu, Y. et al. Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86/JN.1 and EG.5.1/HK.3. Nat. Commun. 15, 8728 (2024).
Kaku, Y. et al. Virological characteristics of the SARS-CoV-2 JN.1 variant. Lancet Infect. Dis. 24, e82 (2024).
Yang, S. et al. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. Lancet Infect. Dis. 24, e70–e72 (2024).
Wang, Q. et al. Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC. Cell Rep. 44, 115543 (2025).
World Health Organization Technical Advisory Group on Virus Evolution. Risk Evaluation for SARS-CoV-2 Variant Under Monitoring: NB.1.8.1 https://www.who.int/publications/m/item/risk-evaluation-for-sars-cov-2-variant-under-monitoring-nb.1.8.1 (WHO, 2025).
World Health Organization Technical Advisory Group on Virus Evolution. Risk Evaluation for SARS-CoV-2 Variant Under Monitoring: XFG https://www.who.int/publications/m/item/risk-evaluation-for-sars-cov-2-variant-under-monitoring-xfg (WHO, 2025).
Mellis, I. A. et al. Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants. Cell Rep. 44, 116440 (2025).
Dong, E. et al. The Johns Hopkins University Center for Systems Science and Engineering COVID-19 Dashboard: data collection process, challenges faced, and lessons learned. Lancet Infect. Dis. 22, e370–e376 (2022).
Dadonaite, B. et al. Spike deep mutational scanning helps predict success of SARS-CoV-2 clades. Nature 631, 617–626 (2024).
Ghosh, S. et al. Beta-coronaviruses use lysosomes for egress instead of the biosynthetic secretory pathway. Cell 183, 1520–1535.e1514 (2020).
Chen, D. et al. ORF3a of SARS-CoV-2 promotes lysosomal exocytosis-mediated viral egress. Dev. Cell 56, 3250–3263.e3255 (2021).
Vaarala, M. H., Porvari, K. S., Kellokumpu, S., Kyllonen, A. P. & Vihko, P. T. Expression of transmembrane serine protease TMPRSS2 in mouse and human tissues. J. Pathol. 193, 134–140 (2001).
Meng, B. et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature 603, 706–714 (2022).
da Costa, C. H. S., de Freitas, C. A. B., Alves, C. N. & Lameira, J. Assessment of mutations on RBD in the spike protein of SARS-CoV-2 Alpha, Delta and Omicron variants. Sci. Rep. 12, 8540 (2022).
Taylor, A. L. & Starr, T. N. Deep mutational scanning of SARS-CoV-2 Omicron BA.2.86 and epistatic emergence of the KP.3 variant. Virus Evol. 10, veae067 (2024).
Yajima, H. et al. Structural basis for receptor-binding domain mobility of the spike in SARS-CoV-2 BA.2.86 and JN.1. Nat. Commun. 15, 8574 (2024).
Tamura, T. et al. Virological characteristics of the SARS-CoV-2 BA.2.86 variant. Cell Host Microbe 32, 170–180.e112 (2024).
Tamura, T. et al. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Nat. Commun. 14, 2800 (2023).
Ito, J. et al. Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant. Nat. Commun. 14, 2671 (2023).
Kim, S. M. et al. SARS-CoV-2 variants with NSP12 P323L/G671S mutations display enhanced virus replication in ferret upper airways and higher transmissibility. Cell Rep. 42, 113077 (2023).
Taha, T. Y. et al. Rapid assembly of SARS-CoV-2 genomes reveals attenuation of the Omicron BA.1 variant through NSP6. Nat. Commun. 14, 2308 (2023).
Taha, T. Y. et al. Enhanced RNA replication and pathogenesis in recent SARS-CoV-2 variants harboring the L260F mutation in NSP6. PLoS Pathog. 21, e1013020 (2025).
Furusawa, Y., Iwatsuki-Horimoto, K., Yamayoshi, S. & Kawaoka, Y. The NSP6-L260F substitution in SARS-CoV-2 BQ.1.1 and XBB.1.16 lineages compensates for the reduced viral polymerase activity caused by mutations in NSP13 and NSP14. J. Virol. 99, e0065625 (2025).
Reuschl, A. K. et al. Evolution of enhanced innate immune suppression by SARS-CoV-2 Omicron subvariants. Nat. Microbiol. 9, 451–463 (2024). Showed the evolution of the enhanced innate immune suppression capabilities by newer SARS-CoV-2 Omicron subvariants.
Zhang, S., Wang, L. & Cheng, G. The battle between host and SARS-CoV-2: innate immunity and viral evasion strategies. Mol. Ther. 30, 1869–1884 (2022).
Kanneganti, T. D. Intracellular innate immune receptors: life inside the cell. Immunol. Rev. 297, 5–12 (2020).
Nie, Y. et al. SARS-CoV-2 ORF3a positively regulates NF-kB activity by enhancing IKKβ–NEMO interaction. Virus Res. 328, 199086 (2023).
Xu, H. et al. SARS-CoV-2 viroporin encoded by ORF3a triggers the NLRP3 inflammatory pathway. Virology 568, 13–22 (2022).
Chen, J. et al. Severe acute respiratory syndrome coronavirus 2 ORF8 protein inhibits type I interferon production by targeting HSP90B1 signaling. Front. Cell Infect. Microbiol. 12, 899546 (2022).
Theobald, S. J. et al. Long-lived macrophage reprogramming drives spike protein-mediated inflammasome activation in COVID-19. EMBO Mol. Med. 13, e14150 (2021).
Zheng, M. et al. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat. Immunol. 22, 829–838 (2021).
Campbell, G. R., To, R. K., Hanna, J. & Spector, S. A. SARS-CoV-2, SARS-CoV-1, and HIV-1 derived ssRNA sequences activate the NLRP3 inflammasome in human macrophages through a non-classical pathway. iScience 24, 102295 (2021).
Barnett, K. C. et al. An epithelial–immune circuit amplifies inflammasome and IL-6 responses to SARS-CoV-2. Cell Host Microbe 31, 243–259.e246 (2023).
Yamada, T. et al. RIG-I triggers a signaling-abortive anti-SARS-CoV-2 defense in human lung cells. Nat. Immunol. 22, 820–828 (2021).
Yin, X. et al. MDA5 governs the innate immune response to SARS-CoV-2 in lung epithelial cells. Cell Rep. 34, 108628 (2021).
Zhang, K. et al. Nsp1 protein of SARS-CoV-2 disrupts the mRNA export machinery to inhibit host gene expression. Sci. Adv. 7, eabe7386 (2021).
Freitas, R. S., Crum, T. F. & Parvatiyar, K. SARS-CoV-2 spike antagonizes innate antiviral immunity by targeting interferon regulatory factor 3. Front. Cell Infect. Microbiol. 11, 789462 (2021).
Moustaqil, M. et al. SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species. Emerg. Microbes Infect. 10, 178–195 (2021).
Naik, N. G., Lee, S. C., Veronese, B. H. S., Ma, Z. & Toth, Z. Interaction of HDAC2 with SARS-CoV-2 NSP5 and IRF3 Is not required for NSP5-Mediated inhibition of type I interferon signaling pathway. Microbiol. Spectr. 10, e0232222 (2022).
Hsu, J. C., Laurent-Rolle, M., Pawlak, J. B., Wilen, C. B. & Cresswell, P. Translational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein. Proc. Natl Acad. Sci. USA 118, e2101161118 (2021).
Kato, K. et al. Overexpression of SARS-CoV-2 protein ORF6 dislocates RAE1 and NUP98 from the nuclear pore complex. Biochem. Biophys. Res. Commun. 536, 59–66 (2021).
Wu, J. et al. SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO. Cell Rep. 34, 108761 (2021).
Xia, H. et al. Evasion of type I interferon by SARS-CoV-2. Cell Rep. 33, 108234 (2020).
Yuen, C. K. et al. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists. Emerg. Microbes Infect. 9, 1418–1428 (2020).
Moriyama, M., Lucas, C., Monteiro, V. S., Iwasaki, A., & Yale SARS-CoV-2 Genomic Surveillance Initiative. Enhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants. Proc. Natl Acad. Sci. USA 120, e2221652120 (2023).
Li, Y. et al. The R203M and D377Y mutations of the nucleocapsid protein promote SARS-CoV-2 infectivity by impairing RIG-I-mediated antiviral signaling. PLoS Pathog. 21, e1012886 (2025).
Miao, G. et al. ORF3a of the COVID-19 virus SARS-CoV-2 blocks HOPS complex-mediated assembly of the SNARE complex required for autolysosome formation. Dev. Cell 56, 427–442.e425 (2021).
Shi, Y. et al. Mutations accumulated in the spike of SARS-CoV-2 Omicron allow for more efficient counteraction of the restriction factor BST2/Tetherin. PLoS Pathog. 20, e1011912 (2024).
Wu, H. et al. Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2. Cell Host Microbe 29, 1788–1801.e1786 (2021).
Syed, A. M. et al. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. Proc. Natl Acad. Sci. USA 119, e2200592119 (2022).
Cochin, M. et al. The SARS-CoV-2 Alpha variant exhibits comparable fitness to the D614G strain in a Syrian hamster model. Commun. Biol. 5, 225 (2022).
Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583, 834–838 (2020).
Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl Acad. Sci. USA 117, 16587–16595 (2020).
Saito, A. et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature 602, 300–306 (2022).
Halfmann, P. J. et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature 603, 687–692 (2022). Demonstrated that the SARS-CoV-2 Omicron variant causes attenuated (milder) disease in mice and hamsters relative to earlier strains.
Shuai, H. et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature 603, 693–699 (2022).
Suzuki, R. et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature 603, 700–705 (2022).
Uraki, R. et al. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents. Nature 612, 540–545 (2022).
Tamura, T. et al. Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5. Commun. Biol. 6, 772 (2023).
Imbiakha, B. et al. Age-dependent acquisition of pathogenicity by SARS-CoV-2 Omicron BA.5. Sci. Adv. 9, eadj1736 (2023).
Stewart, R. et al. SARS-CoV-2 omicron BA.5 and XBB variants have increased neurotropic potential over BA.1 in K18-hACE2 mice and human brain organoids. Front. Microbiol. 14, 1320856 (2023).
Rizvi, Z. A. et al. Omicron sub-lineage BA.5 infection results in attenuated pathology in hACE2 transgenic mice. Commun. Biol. 6, 935 (2023).
Uraki, R. et al. Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates. Nat. Commun. 14, 1620 (2023).
Case, J. B. et al. Characterization of the SARS-CoV-2 BA.5.5 and BQ.1.1 Omicron variants in mice and hamsters. J. Virol. 97, e0062823 (2023).
Halfmann, P. J. et al. Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters. Commun. Biol. 7, 331 (2024).
Halfmann, P. J. et al. Transmission and re-infection of Omicron variant XBB.1.5 in hamsters. EBioMedicine 93, 104677 (2023).
Tamura, T. et al. Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant. Nat. Commun. 15, 1176 (2024).
Izadi, A. et al. Protective non-neutralizing anti-N-terminal domain mAb maintains Fc-mediated function against SARS-COV-2 variants up to BA.2.86-JN.1 with superfluous in vivo protection against JN.1 due to attenuated virulence. J. Immunol. 213, 678–689 (2024).
Wolter, N. et al. Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa. Nat. Commun. 13, 5860 (2022).
Wolter, N., Jassat, W., von Gottberg, A., Cohen, C. & DATCOV-Gen author group. Clinical severity of omicron lineage BA.2 infection compared with BA.1 infection in South Africa. Lancet 400, 93–96 (2022).
Mefsin, Y. M. et al. Epidemiology of Infections with SARS-CoV-2 Omicron BA.2 variant, Hong Kong, January–March 2022. Emerg. Infect. Dis. 28, 1856–1858 (2022).
Port, J. R. et al. Increased small particle aerosol transmission of B.1.1.7 compared with SARS-CoV-2 lineage A in vivo. Nat. Microbiol. 7, 213–223 (2022).
Munoz-Fontela, C. et al. Animal models for COVID-19. Nature 586, 509–515 (2020).
Port, J. R. et al. SARS-CoV-2 disease severity and transmission efficiency is increased for airborne compared to fomite exposure in Syrian hamsters. Nat. Commun. 12, 4985 (2021).
Liu, Y. et al. The N501Y spike substitution enhances SARS-CoV-2 infection and transmission. Nature 602, 294–299 (2022).
Zhou, B. et al. SARS-CoV-2 spike D614G change enhances replication and transmission. Nature 592, 122–127 (2021).
Boon, A. C. M. et al. Reduced airborne transmission of SARS-CoV-2 BA.1 Omicron virus in Syrian hamsters. PLoS Pathog. 18, e1010970 (2022).
Su, W. et al. Reduced pathogenicity and transmission potential of omicron BA.1 and BA.2 sublineages compared with the early severe acute respiratory syndrome coronavirus 2 D614G variant in syrian hamsters. J. Infect. Dis. 227, 1143–1152 (2023).
Hall, V. et al. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N. Engl. J. Med. 386, 1207–1220 (2022). A large-scale analysis of the level of protection achieved through inoculation and prior infection.
Tseng, H. F. et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat. Med. 28, 1063–1071 (2022).
Watanabe, A., Iwagami, M., Yasuhara, J., Takagi, H. & Kuno, T. Protective effect of COVID-19 vaccination against long COVID syndrome: a systematic review and meta-analysis. Vaccine 41, 1783–1790 (2023).
Nguyen, D. C. et al. SARS-CoV-2-specific plasma cells are not durably established in the bone marrow long-lived compartment after mRNA vaccination. Nat. Med. https://doi.org/10.1038/s41591-024-03278-y (2024).
Liang, C. Y. et al. Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines. Nature 630, 950–960 (2024). Demonstrated that ancestor-strain mRNA vaccination imprints the human immune response to Omicron boosters, focusing cross-neutralizing antibodies effective against diverse variants.
Yisimayi, A. et al. Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting. Nature 625, 148–156 (2024). Demonstrated that repeated exposure to Omicron can override the immune imprinting caused by ancestral SARS-CoV-2 vaccines.
Johnston, T. S. et al. Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants. Immunity 57, 912–925.e914 (2024). Demonstrated that prior antigen exposure constrains how a person’s circulating immune defenses focus their fight against newly evolved viral forms.
World Health Organization. Statement on the Antigen Composition of COVID-19 Vaccines https://www.who.int/news/item/26-04-2024-statement-on-the-antigen-composition-of-covid-19-vaccines (WHO, 2024).
World Health Organization. Statement on the Antigen Composition of COVID-19 Vaccines https://www.who.int/news/item/15-05-2025-statement-on-the-antigen-composition-of-covid-19-vaccines (WHO, 2025).
Rydyznski Moderbacher, C. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183, 996–1012.e1019 (2020).
Oja, A. E. et al. Divergent SARS-CoV-2-specific T- and B-cell responses in severe but not mild COVID-19 patients. Eur. J. Immunol. 50, 1998–2012 (2020).
de Silva, T. I. et al. The impact of viral mutations on recognition by SARS-CoV-2 specific T cells. iScience 24, 103353 (2021).
Kim, G. J. et al. A bioinformatic analysis of T-cell epitope diversity in SARS-CoV-2 variants: association with COVID-19 clinical severity in the United States population. Front. Immunol. 15, 1357731 (2024).
Tye, E. X. C. et al. Mutations in SARS-CoV-2 spike protein impair epitope-specific CD4+ T cell recognition. Nat. Immunol. 23, 1726–1734 (2022).
da Silva Antunes, R. et al. Evolution of SARS-CoV-2 T cell responses as a function of multiple COVID-19 boosters. Cell Rep. 44, 115907 (2025).
Zhuang, Z. et al. Harnessing T-cells for enhanced vaccine development against viral infections. Vaccines 12, 478 (2024).
Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. N. Engl. J. Med. 384, 238–251 (2021).
Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290–295 (2020).
Dong, J. et al. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nat. Microbiol. 6, 1233–1244 (2021).
Takashita, E. et al. Efficacy of antibodies and antiviral drugs against COVID-19 omicron variant. N. Engl. J. Med. 386, 995–998 (2022).
Takashita, E. et al. Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant BA.2. N. Engl. J. Med. 386, 1475–1477 (2022).
Takashita, E. et al. Efficacy of antiviral agents against the Omicron subvariant BA.2.75. N. Engl. J. Med. 387, 1236–1238 (2022).
Takashita, E. et al. In vitro efficacy of antiviral agents against Omicron subvariant BA.4.6. N. Engl. J. Med. 387, 2094–2097 (2022).
Takashita, E. et al. Efficacy of antibodies and antiviral drugs against Omicron BA.2.12.1, BA.4, and BA.5 subvariants. N. Engl. J. Med. 387, 468–470 (2022).
Westendorf, K. et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep. 39, 110812 (2022).
Imai, M. et al. Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB. N. Engl. J. Med. 388, 89–91 (2023).
Uraki, R. et al. Antiviral and bivalent vaccine efficacy against an Omicron XBB.1.5 isolate. Lancet Infect. Dis. 23, 402–403 (2023).
Bock, A. New guidance helps clinicians use pemivibart to protect immunocompromised patients from COVID-19. JAMA https://doi.org/10.1001/jama.2024.18589 (2024).
Planas, D. et al. Escape of SARS-CoV-2 variants KP.1.1, LB.1, and KP3.3 From approved monoclonal antibodies. Pathog. Immun. 10, 1–11 (2024).
Wang, Q., Guo, Y., Ho, J. & Ho, D. D. Activity of research-grade pemivibart against recent SARS-CoV-2 JN.1 sublineages. N. Engl. J. Med. 391, 1863–1864 (2024).
Cihlar, T. & Mackman, R. L. Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19. Antivir. Ther. 27, 13596535221082773 (2022).
Sheahan, T. P. et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. 9, eaal3653 (2017).
Agostini, M. L. et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9, e00221–18 (2018).
Murphy, B. G. et al. The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. Vet. Microbiol. 219, 226–233 (2018).
Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269–271 (2020).
Cho, A. et al. Synthesis and antiviral activity of a series of 1′-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorg. Med. Chem. Lett. 22, 2705–2707 (2012).
Beigel, J. H. et al. Remdesivir for the treatment of COVID-19 — final report. N. Engl. J. Med. 383, 1813–1826 (2020).
Wang, Y. et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395, 1569–1578 (2020).
Li, G., Hilgenfeld, R., Whitley, R. & De Clercq, E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat. Rev. Drug. Discov. 22, 449–475 (2023). Summarized the rapid advancements in COVID-19 drug discovery; discussed small-molecule antivirals, monoclonal antibodies and immunomodulatory agents; and detailed the essential lessons learned to help combat future outbreaks.
Sanderson, T. et al. A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes. Nature 623, 594–600 (2023).
Iketani, S. et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature 613, 558–564 (2023).
Owen, D. R. et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586–1593 (2021).
Unoh, Y. et al. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J. Med. Chem. 65, 6499–6512 (2022).
Yotsuyanagi, H. et al. Efficacy and safety of 5-day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial. JAMA Netw. Open. 7, e2354991 (2024).
Heyer, A. et al. Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection. Cell Rep. Med. 3, 100735 (2022).
Zuckerman, N. S., Bucris, E., Keidar-Friedman, D., Amsalem, M. & Brosh-Nissimov, T. Nirmatrelvir resistance — de dovo E166V/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir/ritonavir monotherapy leading to clinical and virological treatment failure — a case report. Clin. Infect. Dis. 78, 352–355 (2024).
Raglow, Z. et al. SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis. Lancet Microbe 5, e235–e246 (2024).
Victora, G. D. & Nussenzweig, M. C. Germinal centers. Annu. Rev. Immunol. 40, 413–442 (2022).
Matz, H. C., McIntire, K. M. & Ellebedy, A. H. ‘Persistent germinal center responses: slow-growing trees bear the best fruits’. Curr. Opin. Immunol. 83, 102332 (2023).
Francis, T. On the doctrine of original antigenic sin. Proc. Am. Philos. Soc. 104, 572–578 (1960).
Monto, A. S., Malosh, R. E., Petrie, J. G. & Martin, E. T. The doctrine of original antigenic sin: separating good from evil. J. Infect. Dis. 215, 1782–1788 (2017).
Koutsakos, M. & Ellebedy, A. H. Immunological imprinting: understanding COVID-19. Immunity 56, 909–913 (2023).
Christensen, P. A. et al. Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with coronavirus disease 2019 caused by the omicron variant of severe acute respiratory syndrome coronavirus 2 in Houston, Texas. Am. J. Pathol. 192, 642–652 (2022).
Wang, Q. et al. Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6. Lancet Infect. Dis. 23, e397–e398 (2023).
Ying, B. et al. Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice. Cell 185, 1572–1587.e1511 (2022).
Scheaffer, S. M. et al. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice. Nat. Med. https://doi.org/10.1038/s41591-022-02092-8 (2022).
Reynolds, C. J. et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science 377, eabq1841 (2022).
Park, Y. J. et al. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. Science 378, 619–627 (2022).
Gagne, M. et al. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. Cell 185, 1556–1571.e1518 (2022).
Alsoussi, W. B. et al. SARS-CoV-2 Omicron boosting induces de novo B cell response in humans. Nature 617, 592–598 (2023).
Tortorici, M. A. et al. Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans. Immunity 57, 904–911.e904 (2024).
Pušnik, J. et al. Vaccination impairs de novo immune response to Omicron breakthrough infection, a precondition for the original antigenic sin. Nat. Commun. 15, 3102 (2024).
Voss, W. N. et al. Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination. Cell Rep. Med. 5, 101668 (2024).
Chen, Y. et al. SARS-CoV-2 Omicron infection augments the magnitude and durability of systemic and mucosal immunity in triple-dose CoronaVac recipients. mBio 15, e0240723 (2024).
Jin, L., Li, Z., Zhang, X., Li, J. & Zhu, F. CoronaVac: a review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2. Hum. Vaccin. Immunother. 18, 2096970 (2022).
Schiepers, A. et al. Molecular fate-mapping of serum antibody responses to repeat immunization. Nature 615, 482–489 (2023).
Wang, Q. et al. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host Microbe 32, 315–321.e313 (2024).
Huang, C. Q., Vishwanath, S., Carnell, G. W., Chan, A. C. Y. & Heeney, J. L. Immune imprinting and next-generation coronavirus vaccines. Nat. Microbiol. 8, 1971–1985 (2023).
Kim, J. H., Davis, W. G., Sambhara, S. & Jacob, J. Strategies to alleviate original antigenic sin responses to influenza viruses. Proc. Natl Acad. Sci. USA 109, 13751–13756 (2012).
Costa Rocha, V. P. et al. A polyvalent RNA vaccine reduces the immune imprinting phenotype in mice and induces neutralizing antibodies against omicron SARS-CoV-2. Heliyon 10, e25539 (2024).
Musunuri, S., Weidenbacher, P. A. B. & Kim, P. S. Bringing immunofocusing into focus. npj Vaccines 9, 11 (2024).
Dugan, H. L. et al. Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. Immunity 54, 1290–1303.e1297 (2021).
Topol, E. J. & Iwasaki, A. Operation nasal vaccine-lightning speed to counter COVID-19. Sci. Immunol. 7, eadd9947 (2022).
Mao, T. et al. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science 378, eabo2523 (2022).
Kuroda, M. et al. SARS-CoV-2 virus lacking the envelope and membrane open-reading frames as a vaccine platform. Nat. Commun. 16, 4453 (2025).
Schon, J. et al. A safe, effective and adaptable live-attenuated SARS-CoV-2 vaccine to reduce disease and transmission using one-to-stop genome modifications. Nat. Microbiol. 9, 2099–2112 (2024).
Tang, R. et al. Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial. Lancet Respir. Med. 11, 613–623 (2023).
Li, J. X. et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir. Med. 10, 739–748 (2022).
Singh, C. et al. Phase III pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin). npj Vaccines 8, 125 (2023).
Carvalho, T. Intranasal COVID-19 vaccine fails to induce mucosal immunity. Nat. Med. 28, 2439–2440 (2022).
Madhavan, M. et al. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: an open-label partially-randomised ascending dose phase I trial. EBioMedicine 85, 104298 (2022).
Zhu, F. et al. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 11, 1075–1088 (2023).
Bachmann, M. F., Mohsen, M. O., Zha, L., Vogel, M. & Speiser, D. E. SARS-CoV-2 structural features may explain limited neutralizing-antibody responses. npj Vaccines 6, 2 (2021).
Slifka, M. K. & Amanna, I. J. Role of multivalency and antigenic threshold in generating protective antibody responses. Front. Immunol. 10, 956 (2019).
Pardi, N. et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J. Exp. Med. 215, 1571–1588 (2018).
Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data — from vision to reality. Eur. Surveill. 22, 30494 (2017).
de Bernardi Schneider, A. et al. SARS-CoV-2 lineage assignments using phylogenetic placement/UShER are superior to pangoLEARN machine-learning method. Virus Evol. 10, vead085 (2024).
Hinrichs, A., Ye, C., Turakhia, Y. & Corbett-Detig, R. The ongoing evolution of UShER during the SARS-CoV-2 pandemic. Nat. Genet. 56, 4–7 (2024).
Hui, K. P. Y. et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature 603, 715–720 (2022).
Hoffmann, M. et al. Omicron subvariant BA.5 efficiently infects lung cells. Nat. Commun. 14, 3500 (2023).
Midgley, C. M. et al. An in-depth analysis of original antigenic sin in Dengue virus infection. J. Virol. 85, 410–421 (2011).
St John, A. L. & Rathore, A. P. S. Adaptive immune responses to primary and secondary dengue virus infections. Nat. Rev. Immunol. 19, 218–230 (2019).
McCray, P. B. Jr. et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 81, 813–821 (2007).
Winkler, E. S. et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 21, 1327–1335 (2020).
Zheng, J. et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature 589, 603–607 (2021).
Pons-Grifols, A. et al. A human-ACE2 knock-in mouse model for SARS-CoV-2 infection recapitulates respiratory disorders but avoids neurological disease associated with the transgenic K18-hACE2 model. mBio 16, e0072025 (2025).
Hassan, A. O. et al. A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell 182, 744–753.e744 (2020).
Israelow, B. et al. Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. J. Exp. Med. 217, e20201241 (2020).
Dinnon, K. H. 3rd et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature 586, 560–566 (2020).
Gu, H. et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science 369, 1603–1607 (2020).
Leist, S. R. et al. A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice. Cell 183, 1070–1085.e1012 (2020).
Enkirch, T. & von Messling, V. Ferret models of viral pathogenesis. Virology 479–480, 259–270 (2015).
Johnston, S. C. et al. Development of a coronavirus disease 2019 nonhuman primate model using airborne exposure. PLoS ONE 16, e0246366 (2021).
Lu, S. et al. Comparison of nonhuman primates identified the suitable model for COVID-19. Signal Transduct. Target. Ther. 5, 157 (2020).
Singh, D. K. et al. Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets. Nat. Microbiol. 6, 73–86 (2021).
